Skip to main content
. Author manuscript; available in PMC: 2023 Apr 7.
Published in final edited form as: Mol Cancer Ther. 2022 Oct 7;21(10):1573–1582. doi: 10.1158/1535-7163.MCT-22-0192

Figure 5: AIDE co-administration improves the response of NCI-N87 xenografts to trastuzumab-gelonin.

Figure 5:

Provided is the (A) tumor volume over time, (B) Kaplan-Meier survival curves and (C) change in body weight of NCI-N87 xenograft bearing mice following a single intravenous injection of PBS (open circles), 2.5 mg/kg trastuzumab-gelonin (open squares), 2.5 mg/kg trastuzumab-gelonin+LE8 (closed circles) and 2.5 mg/kg trastuzumab-gelonin+1HE (closed squares). Data is presented as the group mean (n=5 for the PBS group, 6 for trastuzumab gelonin treated groups) with standard deviation error bars.